94 related articles for article (PubMed ID: 9510368)
1. Functional characterization of HLA-DRA1*0101/DRB1*0401 molecules expressed in Drosophila melanogaster cells.
Hansen BE; Andersson EC; Madsen LS; Engberg J; Søndergaard L; Svejgaard A; Fugger L
Tissue Antigens; 1998 Feb; 51(2):119-28. PubMed ID: 9510368
[TBL] [Abstract][Full Text] [Related]
2. Prediction of peptide affinity to HLA DRB1*0401.
Marshall KW; Wilson KJ; Liang J; Woods A; Zaller D; Rothbard JB
J Immunol; 1995 Jun; 154(11):5927-33. PubMed ID: 7751636
[TBL] [Abstract][Full Text] [Related]
3. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.
Kirschmann DA; Duffin KL; Smith CE; Welply JK; Howard SC; Schwartz BD; Woulfe SL
J Immunol; 1995 Dec; 155(12):5655-62. PubMed ID: 7499850
[TBL] [Abstract][Full Text] [Related]
4. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
Monji T; McCormack AL; Yates JR; Pious D
J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
[TBL] [Abstract][Full Text] [Related]
5. Inefficient peptide binding by cell-surface class II MHC molecules.
Sherman MA; Weber DA; Spotts EA; Moore JC; Jensen PE
Cell Immunol; 1997 Nov; 182(1):1-11. PubMed ID: 9427804
[TBL] [Abstract][Full Text] [Related]
6. MHC class II presentation of human acetylcholine receptor in Myasthenia gravis: binding of synthetic gamma subunit sequences to DR molecules.
Yuen MH; Macklin KD; Conti-Fine BM
J Autoimmun; 1996 Feb; 9(1):67-77. PubMed ID: 8845056
[TBL] [Abstract][Full Text] [Related]
7. Counter-antigen presentation: fibroblasts produce cytokines by signalling through HLA class II molecules without inducing T-cell proliferation.
Ohyama H; Nishimura F; Meguro M; Takashiba S; Murayama Y; Matsushita S
Cytokine; 2002 Feb; 17(4):175-81. PubMed ID: 11991669
[TBL] [Abstract][Full Text] [Related]
8. Cellular mechanisms of exogenous peptide binding to HLA class II molecules in B cells.
Frumento G; de Totero D; Ferrara GB; Chersi A; Pernis B
Cell Immunol; 1994 Apr; 155(1):1-10. PubMed ID: 8168138
[TBL] [Abstract][Full Text] [Related]
9. Antigen presentation mediated by recycling of surface HLA-DR molecules.
Pinet V; Vergelli M; Martin R; Bakke O; Long EO
Nature; 1995 Jun; 375(6532):603-6. PubMed ID: 7540726
[TBL] [Abstract][Full Text] [Related]
10. Identification of HLA-DRB1-bound self-peptides following measles virus infection.
Ovsyannikova IG; Johnson KL; Naylor S; Poland GA
J Immunol Methods; 2005 Feb; 297(1-2):153-67. PubMed ID: 15777939
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness.
Godkin A; Davenport M; Hill AV
Hepatology; 2005 Jun; 41(6):1383-90. PubMed ID: 15915462
[TBL] [Abstract][Full Text] [Related]
12. A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation.
Woulfe SL; Bono CP; Zacheis ML; Welply JK; Kirschmann DA; Baudino TA; Wang Y; Stone DA; Hanson GJ; Vuletich JL; Bedell LJ; Schwartz BD; Howard SC
J Pharmacol Exp Ther; 1997 May; 281(2):663-9. PubMed ID: 9152371
[TBL] [Abstract][Full Text] [Related]
13. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
15. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells.
Nygard NR; Giacoletto KS; Bono C; Gorka J; Kompelli S; Schwartz BD
J Immunol; 1994 Feb; 152(3):1082-93. PubMed ID: 8301118
[TBL] [Abstract][Full Text] [Related]
16. Specific overexpression of rheumatoid arthritis-associated HLA-DR alleles and presentation of low-affinity peptides.
Kerlan-Candon S; Louis-Plence P; Wiedemann A; Combe B; Clot J; Eliaou JF; Pinet V
Arthritis Rheum; 2001 Jun; 44(6):1281-92. PubMed ID: 11407687
[TBL] [Abstract][Full Text] [Related]
17. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
18. HLA-DR4 (DRB1*0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response.
Pan S; Trejo T; Hansen J; Smart M; David CS
J Immunol; 1998 Sep; 161(6):2925-9. PubMed ID: 9743354
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
Cheng YJ; Zhou Q; Li ZG
Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743
[TBL] [Abstract][Full Text] [Related]
20. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
